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chronic GvHD; one with Etanercept, Cyclosporine and Sol-
umedrol and one with Orapred and Imuran. One patient was
still on prophylactic Tacrolimus when hyperthyroidism was
diagnosed 9 months after transplant. All patients required a
form of ablative therapy. Two received radioactive iodine as
treatment. Three patients received Methimazole alone. One
patient failed Methimazole, received radioactive iodine and
then underwent thyroidectomy revealing follicular carci-
noma. One of the patients did not receive any therapy; he
had Hoshimoto’s thyroidits and went on to develop hypo-
thyroidism. Another patient had a total thyroidectomy that
revealed diffuse hyperplasia. All patients are surviving 1 to 9










Male 14 (61%) 47 (68%) 0.61
Mean Age in Yrs (95% CI) 9.6 (6.3-12.9) 6.9 (5.5-8.2) 0.068
Diagnosis 0.36
Malignancy 12 (51%) 22 (32%)
Immune deﬁciency 5 (21%) 29 (42%)
Bone Marrow Failure 5 (21%) 15 (22%)
Genetic/Metabolic 1 (7%) 2 (3%)
Benign Hematology 0 1 (1%)
Therapy / Conditioning
Previous anthracycline 11 (48%) 18 (26%) 0.070
RIC 12 (52%) 42 (61%) 0.47
Myeloablative 11 (48%) 27 (39%)
Donor 0.11
Autologous 7 (30%) 9 (13%)
Allogeneic 16 (70%) 60 (87%)
Source 0.032
Bone Marrow 11 (48%) 43 (62%)
Cord 0 8 (12%)
PBSC 12 (52%) 18 (26%)
Type 0.14
Auto 7 (30%) 9 (13%)
Related Donor 3 (13%) 8 (12%)
Unrelated Donor 13 (57%) 52 (75%)
Transplant Complications
GVHD 5 (22%) 26 (38%) 0.21
Engraftment Syndrome 1 (4%) 11 (16%) 0.28
Adenovirus 4 (17%) 12 (17%) 1.00
CMV 3 (13%) 19 (28%) 0.26
EBV 7 (30%) 31 (45%) 0.33
Death at 1 year 5 (22%) 14 (20%) 1.00286
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Background: Neuroblastoma (NB) is a pediatric tumor of
neural crest origin. It is one of several small round blue cell
tumors. Patients who have MYC-N ampliﬁed tumors that
respond sub-optimally to initial therapies have poor out-
comes with 30-40% long-term survival. These tumors may
have a higher content of therapy resistant cancer stem cells
that utilize autophagy as an enhanced survival mechanism.
In the following study we identiﬁed a stem cell phenotype in
an MYC-N ampliﬁed neuroblastoma cell line from ATCC (BE-
2) and investigated the activity of two new classes of drugs
(GLUT-1 inhibitors and bisquinolone antimalarials).
Methods: Flow cytometry was utilized to identify stem cell
fractions within an unselected BE-2 population. Brieﬂy, in
side population analysis 1 x 106 cells were incubated with
Hoescht IMDM staining media (1 mcg/ml) and incubated for
30 minutes with Hoechst 33342 dye. Cells were then kept on
ice until ﬂow cytometry analysis. Flow cytometry was per-
formed using a BD FACSAria. Autophagy was measured using
a ﬂow cytometry based assay measuring membrane bound
LC3 (Milipore Inc). Screening assays for drug activity used a
96 well platform with MTT to measure cytotoxicity of bis-
quinolone and GLUT-1 cytotoxicity. Neurospheres were
grown in non-adherent plates to assess activity in this stem
cell enriched screening assay.
Results: Flow cytometry demonstrated a high percent of side
population cells on three separate analyses (11%, 38%, 28% of
live cells). In comparison twomurine breast cancer cells lines
(Clone 66 and 4T1) and human mantle cell line (Granta) side
population fractions were approximately 1% of live cells. A
commercially available bisquinolone, hydroxychloroquine,
demonstrated the ability to inhibit autophagy as measured
by the ﬂow cytometry assay. Using the two in-vitro screening
assays described above, a number of bisquinolone antima-
larials and GLUT-1 inhibitors were assessed for activity and
three compounds were identiﬁed with high activity (Q2-15
antimalarial and STF-04 and STF-05 GLUT-1 inhibitor).
Conclusion: In the following study we describe a large
cancer stem cell population as measured by side population
assay in BE-2 human neuroblastoma cells. Bisquinolone
antimalarial drugs demonstrated the ability to inhibit auto-
phagy. Both bisquinolone antimalarials and GLUT-1inhibitors demonstrated cytotoxic activity in an MTT assay
and activity in a stem cell enriched neurosphere assay. These
two classes of drugs have the potential to improve therapy in
poor prognostic neuroblastoma and studies combining
candidate compounds are ongoing both in cell culture and an
NSG animal model.
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Background: Cardiac evaluation during ﬁrst 100 days after
stem cell transplant (SCT) is usually performed only if clini-
cally indicated, however, patients with mild left ventricular
(LV) dysfunction can be asymptomatic. Scheduled post-SCT
screening at day 100 may identify patients with subacute
cardiac toxicity identiﬁed as LV dysfunction.
Methods:We conducted a single center prospective study to
screen for LV dysfunction after SCT in 100 consecutive pa-
tients. Patients received echocardiography screening prior to
SCT and 100 days post-SCT. Patients were classiﬁed as having
LV dysfunction if echocardiography met at least one of the
